Reuters reports that Moderna (NASDAQ:MRNA) announced Monday it is lowering its 2025 sales forecast by $1 billion due to weak demand for its COVID-19 vaccines and a slower rollout of its new respiratory syncytial virus (RSV) shot.
The company now expects annual revenue between $1.5 billion and $2.5 billion, primarily in the latter half of the year. That's down from its earlier estimate of $2.5 billion to $3.5 billion and below the $2.95 billion analysts had expected, based on LSEG data.
CEO Stephane Bancel said Moderna plans to cut 2025 cash costs by $1 billion, with another $500 million in reductions targeted for 2026. The company anticipates finishing 2025 with about $6 billion in cash and investments.
Moderna is banking on new products to reignite growth. It has filed for FDA approval of a combination COVID-19 and flu vaccineand expects a decision by May on its next-generation COVID-19 vaccine.The company plans to release its fourth-quarter earnings on Feb. 14.
This article first appeared on GuruFocus.免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。